biotech / news / / MarketScreener
Shares of Zymeworks and Jazz Pharmaceuticals climbed after the companies released what they called positive topline results from a late-stage trial.
Zymeworks and Jazz Pharmaceuticals reported positive topline results from a late-stage zanidatamab-hrii trial.
KEY POINTS
- Zanidatamab-hrii combined with chemotherapy showed a safety profile consistent with known agent profiles.
- The companies plan to submit a supplemental biologics license application for first-line use in 2026.
- Zanidatamab-hrii is currently approved as Ziihera for second-line biliary tract cancer in multiple regions.
- BeOne Medicines is collaborating in the development and commercialization of zanidatamab-hrii.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →